When surgeons operate to remove a tumor, determining exactly where to cut can be tricky. Ideally, the entire tumor should be removed while leaving a continuous layer of healthy tissue, but current techniques for locating the tumors during surgery are imprecise.
Researchers at Johns Hopkins have figured out the three-dimensional shape of the protein responsible for creating unique bonds within the cell wall of the bacteria that cause tuberculosis. The bonds make the bacteria resistant to currently available drug therapies, contributing to the alarming rise of these super-bacteria throughout the world.
A team of UC Davis scientists has shown in experimental mouse models that a new drug delivery system allows for administration of three times the maximum tolerated dose of a standard drug therapy for advanced bladder cancer, leading to more effective cancer control without increasing toxicity.
Mucus coats our airways' internal surfaces. The viscous gel humidifies the lungs and prevents viruses and other small particles like diesel soot from entering the body unchecked. Previously unclear was the extent to which such nanoparticles are able to move through the lungs' mucus. Here, the research evidence was contradictory.
Chesapeake PERL has received a Small Business Innovation Research award from the National Cancer Institute to continue development of a protein nanoparticle linked to an antitumor agent as a potential lung cancer therapeutic. C-PERL collaborators in the laboratory of Dr. Leonard Rome, Professor of Biological Chemistry at UCLA have identified and characterized the vault particle, a unique nanoparticle structure ubiquitous in eukaryotes.
Actinium Pharmaceuticals, Inc., (API), a private biopharmaceutical company that develops innovative targeted radio-immunotherapeutics, announced that the poster summarizing the results for Phase I study of Actimab-A, its antibody directed alpha emitter drug candidate, has won a first place poster presentation award at the 8th Annual Hematologic Malignancies 2012 Conference held in Houston, TX, from October 10-14.
Merck Serono, a division of Merck, Darmstadt, Germany, and Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that they have entered into a strategic agreement focused on Auxogyn's proprietary Early Embryo Viability Assessment (Eeva) Test. Under the terms of the agreement, Merck Serono will provide strategic, scientific and medical support in the development and commercialization of the Eeva™ Test.
Vascular Nanotransfer Technologies (“VNT”), an emerging medical technology company, announced today that large animal model in vivo tests of its paclitaxel nanocarrier-based Drug Coated Balloon (“DCB”) achieved tissue levels comparable to devices with proven clinical efficacy.
Excitement around the potential for targeted nanoparticles (NPs) that can be controlled by stimulus outside of the body for cancer therapy has been growing over the past few years. More specifically, there has been considerable attention around near-infrared (NIR) light as an ideal method to stimulate nanoparticles from outside the body.
An team of Rutgers University scientists led by Richard H. Ebright and Eddy Arnold has determined the three-dimensional structure of the transcription initiation complex, the key intermediate in the process by which cells read out genetic information in DNA.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.